Wizenius

JUNE 28, 2023

Valuation is a complex art that requires a deep understanding of financial modeling and various influencing factors. Below are few factors that shape growth rate assumptions and present real-world examples from different geographies to shed light on the art of valuation. Take your career to new heights in the dynamic world of finance.

DCF 52

DCF Financial Models Financial Modeling Discounted Cash Flow 52

Peak Frameworks

SEPTEMBER 19, 2023

company to hit a $1 trillion valuation , it directly benefited shareholders. Proponents argue that by fulfilling this responsibility, firms indirectly benefit society by driving economic growth and innovation. Comparing and Contrasting Both shareholders and stakeholders play crucial roles, but their focus and perspectives often differ.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Software Equity Group

JANUARY 22, 2024

In 2022 and 2023, a time when M&A transactions in many industries declined due to economic conditions, healthcare M&A deals increased considerably. Thus, these realities are also driving a surge of M&A activity in the healthcare SaaS arena. Click here to fill out our assessment form.

Healthcare 52

Healthcare M&A Valuation Medical 52

Software Equity Group

JANUARY 22, 2024

In 2022 and 2023, a time when M&A transactions in many industries declined due to economic conditions, healthcare M&A deals increased considerably. Thus, these realities are also driving a surge of M&A activity in the healthcare SaaS arena. Click here to fill out our assessment form.

Healthcare 52

Healthcare M&A Valuation Medical 52

Cooley M&A

OCTOBER 29, 2018

In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 The Merger Agreement.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Cooley M&A

JULY 10, 2017

However, where there are too many unaccredited investors, parties may be unwilling or unable to pay the present cash value of the future earn-outs to the unaccredited investors (which would require a valuation of the future earn-outs). acquisitions of pharmaceutical products with clinical, regulatory and/or net sales milestones).

Securities 52

Securities IT Investors M&A 52